Intrexon Corporation, Inc.: Series E $100M

Posted in I - Series E, Q - 2Q11, R - MID ATLANTIC, X - Synthetic Biology, XX - VA

Intrexon (Blacksburg, VA) a commercial-stage synthetic biology company focused on modular DNA control systems to enhance capabilities, improve safety and lower cost in human therapeutics, protein production, industrial products, agricultural biotechnology and animal science next generation synthetic biology company, closed a $100M Series E financing. Participants have included Third Security, New River Management, NewVa [...]

Feb

2010

Evolva, SA: Series B $15.3M

Posted in I - Series B, Q - 4Q09, R - INTERNATIONAL, X - Cardiology, X - Renal, X - Synthetic Biology

Evolva (Switzerland) a clinical-stage synthetic biology small molecule company focused on proteinuri kidney and cardiovascular disease, closed a $15.2M Series B financing bringing the total round up to $42.3M. Participants include Wellington Partners, Aravis Venture Associates, Auriga Partners and Vinci Capital.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Dec

2009

Evolva, SA: Series B $27.5M

Posted in I - Series B, Q - 4Q09, R - INTERNATIONAL, X - Cardiology, X - Renal, X - Synthetic Biology

Evolva (Switzerland) a clinical-stage synthetic biology small molecule company focused on proteinuri kidney and cardiovascular disease, closed a $27,5M Series B financing. Participants include Wellington Partners Venture Capital, Aravis Venture Associates, Auriga Partners and Vinci Capital.

to top of page...